The Memorial Sloan-Kettering Cancer Center (MSKCC

计划入组 3,194 人 · 首次发布于 2012 年 1 月 13 日

A Study Involving Collection of Samples and Data From Sarcoma Patients Receiving Immunotherapy

计划入组 250 人 · 首次发布于 2023 年 11 月 2 日

International Travel Patterns and Health Preparations of Hematopoietic Stem Cell Transplant Recipients at Memorial Sloan-Kettering Cancer Center

计划入组 519 人 · 首次发布于 2012 年 1 月 5 日

SMARCA2 inhibitors (Ryvu Therapeutics/Maria Sklodowska Curie Memorial Cancer Center)

P28z-CAR

Monoclonal antibody BR55-2

MEMORIAL SLOAN-KETTERING CANCER CENTER

United States

Memorial Sloan Kettering Cancer Center

United States

Masaryk Memorial Cancer Institute

Czech Republic

MSK Research: CDK2 Inhibition Overcomes Breast Cancer Drug Resistance, 177Lu-PSMA-617 Shows Promise in Prostate Cancer

QBiotics' Tigilanol Tiglate Achieves 80% Response Rate in Soft Tissue Sarcoma Phase IIa Trial

ROME Therapeutics' Landmark Study Reveals Novel LINE-1 Activity Patterns Across Cancer Types